Sign In
Buy BTGOF
$2.73
+0.130 (+5.00%)
At Close: Jun 03, 2026
BT launches sovereign data platform for business and public sector
04:01am, Thursday, 04'th Dec 2025
Britain's BT launched a sovereign data platform for its public-sector and business customers on Thursday to store and process their data in the country, responding to increasing demand for higher leve
Pindrop Partners with BT to Strengthen Enterprise Call Security Across the UK
05:00am, Wednesday, 12'th Nov 2025
LONDON--(BUSINESS WIRE)--Pindrop, a global leader in authentication and fraud detection, today announced a strategic partnership with BT, one of the world's leading communications service providers, t
BT Group plc (BTGOF) Q2 2026 Earnings Call Transcript
02:26pm, Thursday, 06'th Nov 2025
BT Group plc (OTCPK:BTGOF) Q2 2026 Earnings Call November 6, 2025 5:00 AM EST Company Participants Allison Kirkby - CEO & Director Simon Lowth - CFO & Executive Director Conference Call Participants D
BT Group: Solid performance does little to alter long-term picture, says investment bank
07:33am, Thursday, 06'th Nov 2025
It's never easy to make a silk purse out of a copper wire, and BT Group PLC (LSE:BT.A) latest quarter does little to change the picture. The telecoms group turned in numbers that were broadly in line
BT holds firm on outlook as broadband line losses deepen
02:53am, Thursday, 06'th Nov 2025
BT Group PLC (LSE:BT.A) reported first-half results broadly in line with expectations, as earnings remained flat despite a falling top line, with increased fibre take-up helping offset pressure from c
BT could surprise with even worse broadband losses than market expects
10:23am, Tuesday, 04'th Nov 2025
BT Group PLC (LSE:BT.A) second-quarter results this Thursday may reveal more broadband customers switching away from its Openreach arm than investors expect, reckons UBS. Analyst Polo Tang, who has
Karolinska Development invests SEK 7.5 million to support BOOST Pharma's continued development of BT-101 towards Phase 3
06:06am, Tuesday, 28'th Oct 2025
Stockholm, Sweden – October 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that it has exercised its pro rata participation of SEK 7.5 million in BOOST Pharma's latest
BT said to be planning entry into low-cost mobile market
04:12am, Tuesday, 28'th Oct 2025
BT Group PLC (LSE:BT.A) is weighing a move into the low-cost mobile market, according to a report from the Financial Times. The UK's largest broadband provider has been mulling options including la
BT Group explores new mobile brand, FT reports
01:59am, Tuesday, 28'th Oct 2025
Britain's largest broadband provider BT Group is mulling the launch of a low-cost mobile brand, the Financial Times reported on Tuesday, citing people familiar with the matter.
BT and Barclays tipped as 'major multiyear rebound' in M&A activity seen
11:16am, Monday, 27'th Oct 2025
Momentum in UK and European dealmaking is expected to accelerate in what Morgan Stanley analysts believe will be a "multi-year global M&A rebound", where mining, telecoms and defence sectors are se
BT Group: When Hedges Expire, Rates Should Bump EAT By 5%
10:08am, Sunday, 26'th Oct 2025
The rollout is progressing well, and the undue burden ending soon enough should start to shrink discounts to less burdened peers. Rates are coming down. Not a bad thing given a fair amount of the debt
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
02:55am, Monday, 13'th Oct 2025
- Updated clinical data on BT-001 in combination with pembrolizumab to be presented in a poster - Tumor shrinkage observed in both injected and non-injected lesions LUND, SE / ACCESS Newswire / Octobe
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
02:30am, Monday, 13'th Oct 2025
Poster presentation on BT-001 in combination with pembrolizumab has shown tumor shrinkage in both injected and non-injected lesions Strasbourg, France, and Lund, Sweden, October 13, 2025, 8:30 a.m. C
